Stool-based tests like FIT and stool DNA have made initial colorectal cancer screening easier than ever. However, nearly half of patients with positive results fail to complete their follow-up colonoscopy within a year, driven primarily by bowel prep dread. This post examines real-world care gaps, the 1.8 times higher cancer risk of stalled care, and how Zera Medical is working to bridge these two vital steps.

GLP-1 medications like Ozempic and semaglutide are now used by roughly 1 in 8 US adults, concentrated in the exact 50 to 64 age range colorectal cancer screening targets. New research shows GLP-1 users face more than double the odds of inadequate bowel preparation, and clinical guidance on how to manage it is still catching up. This post breaks down the scale of GLP-1 adoption, what the data shows about its effect on prep quality, and how Zera Medical is rethinking the prep process for patients the standard approach has never served well.

Every couple of years, three of Hollywood's most recognizable comedians turn the night before their colonoscopies into a competition, complete with card games and clear gelatin. It's a funny story, but it points to something serious: bowel prep is still the single biggest reason people delay screening. This post traces the tradition from late-night television to two separate 2024 TV nods, breaks down why the dread is so universal, and looks at how ZeraFlow is designed to move prep out of the home for good.

For more than forty years, nearly every part of the colonoscopy has been modernized: the scope, the imaging, the sedation, even the way quality is measured. The one exception is the preparation, which patients still manage at home much as they did in 1980. This post traces how bowel prep became the last unmodernized step in an otherwise advanced procedure, why that outdated first step quietly undermines everything the technology has gained, and what it means for the millions of people who put off screening because of it.

Colorectal cancer is no longer just a disease of older age; cases are rising rapidly among adults under 50, making it the leading cause of cancer death in this demographic. While medical guidelines adjusted by lowering the recommended screening age to 45, actual patient behavior has not followed suit. This post explores the widening generational divide in cancer data, why traditional bowel prep remains the ultimate barrier to early detection, and how Zera Medical is working to reshape the screening experience.

A colonoscopy is only as good as the prep that comes before it, and up to a third of procedures are compromised by inadequate bowel preparation before the scope is ever advanced. This post breaks down what that failure actually costs: missed lesions, repeat procedures, destabilized clinic schedules, and real erosion in screening economics. It makes the case that inadequate prep is a structural problem built into the at-home model, not a patient failure, and points to ZeraFlow as a clinic-based way to fix it at the source.

Most people who put off a colonoscopy aren't afraid of the procedure. They're avoiding the prep, and the research backs them up: only about a third of newly eligible adults are getting screened, with the at-home preparation cited as the barrier patients dread most. This post looks at why traditional prep drives avoidance, how skipped or failed screenings translate into missed cancers, and why fixing the prep may be the highest-leverage step in colorectal cancer prevention. It also introduces ZeraFlow, our clinic-based approach to removing that barrier.